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 Skeletal muscle serves numerous functional and metabolic roles in human health. 
Consequently, understanding the mechanisms that regulate skeletal muscle hypertrophy is 
pertinent to improving the quality of life, particularly in ageing and diseased populations, but 
also for performance in athletic populations. Resistance exercise (RE) potently stimulates muscle 
protein synthesis (MPS), and thus chronic RE (i.e., resistance training) results in muscle 
hypertrophy. Mechanistically, RE activates the mammalian target of rapamycin complex 1 
(mTORC1) signaling cascade and, in turn, regulates several key downstream components (e.g. 
Ribosomal protein S6 kinase 1 (p70S6K1)) that underpin increases in MPS. AMP-activated 
protein kinase (AMPK) is activated by cellular energy depletion, such as low muscle glycogen 
and increased AMP:ATP and ADP:ATP ratios, and is purported to inhibit mTORC1 activity. 
 Whether muscle glycogen content, independent or dependent of AMPK, influences 
mTORC1-S6K1 signaling and MPS remains unknown; so, a recent article in The Journal of 
Physiology by Knudsen et al. sought to address this aperture in research (Knudsen et al., 2020). 
In a parallel fashion, wild type (WT) and dominant negative α2 AMPK kinase dead (AMPK-KD) 
transgenic mice (12-24 weeks old) were each allocated to untreated, normal glycogen (CON) or 
high glycogen (GLYC) groups. For five days before testing, CON mice underwent standard 
feeding with oral gavage vehicle control and GLYC mice underwent “glycogen loading”; 
specifically, phosphorylase inhibitor CP 316819 and sucrose were administered to increase 
muscle glycogen content. On the test day, mice were fasted for two hours and anaesthetized 
before RE. Unilateral in situ contractions simulated RE and permitted the non-exercised leg to 
serve as a within-animal, rested control. RE consisted of quadriceps muscle stimulation for nine 
1-minute contraction bouts (10 V, 0.1 ms at 100 Hz for 3 seconds every 10 seconds), each 
separated by 30 seconds of rest. Several markers of mTORC1 and AMPK activity were 
measured with immunoblotting immediately (0 h) and 4 hours (4 h) post-RE, including 
AMPKS485/491, S6K1T389, rpS6S235/236 and 4E-BP1T36/45 (refer to full text for complete list). Four 
hours post-RE, MPS was measured using the SUnSET method, and muscle glycogen content 
was measured with a fluorometric method as glycosyl units after HCL hydrolysis. 
The authors reported several exciting and novel findings. First, in untreated mice, RE-
induced mTORC1-S6K1 signaling was not affected by AMPK. Understandably, AMPKS485/491 
activity was only significantly increased in WT mice immediately following RE; however, no 
between-genotype activity differences were observed for several downstream targets of 
mTORC1, including S6K1 and rpS6. Second, following RE, MPS was impaired in untreated 
AMPK-KD mice compared with untreated WT mice. Specifically, MPS increased significantly 
above rested values in the WT (~40%) but not AMPK-KD mice (~15%). Third, the GLYC 
treatment, compared to the CON treatment, increased mTORC1-S6K1 signaling in WT but not 
AMPK-KD mice following RE; namely, S6K1 and rpS6 activation increased in only WT mice. 
Importantly, AMPK-KD mice exhibited lower (~25%) resting glycogen compared to WT mice. 
Glycogen content was significantly elevated above resting values in WT (50%) but not AMPK-
KD (30%) mice, despite glycogen phosphorylaseSer15 being similarly supressed and unaffected 
by contraction in both genotypes. Lastly, within genotypes, GLYC appeared to further augment 
MPS compared to CON in AMPK-KD but not in WT mice. Moreover, when  protein synthesis 
data from untreated and vehicle treated CON mice were combined within-genotypes, protein 
synthesis increased significantly less in AMPK-KD (25%) than WT mice (60%). Since GLYC 
appeared to increase MPS in AMPK-KD mice, the authors suggested that reduced glycogen 
content may diminish MPS independent of mTORC1 signaling. Overall, these data suggest that 
following RE: 1) mTORC1-S6K1 signaling can occur independently of AMPK, 2) a disconnect 
exists between mTORC1-S6K1 signaling and MPS, and 3) muscle glycogen content can 
influence mTORC1-S6K1 signaling and MPS via an unknown mechanism. 
AMPK is frequently reported to blunt MPS via reduced mTORC1 activation in both mice 
and humans, and AMPK has subsequently been considered a negative regulator of mTORC1 
(i.e., the concurrent training effect). Nevertheless, Knudsen et al. demonstrated that mTORC1 
signaling occurs independent of AMPK. The lack of between-genotype differences in 
downstream targets of mTORC1 such as S6K1, rpS6 and 4E-BP1 activity – regardless of 
increased AMPK activity or absence – suggests that AMPK is not necessarily a negative 
regulator of mTORC1 following RE. While AMPK can inhibit mTORC1 activation, the present 
study indicates that increased AMPK activity can exist without inhibiting mTORC1 if sufficient 
mTORC1-activating signals are present; thus, AMPK is not necessarily a tyrannical inhibitor of 
mTORC1. Rather, mTORC1-activating and -inhibiting signals appear to contend with each other 
for mTORC1 activity, with glycogen content influencing the outcome via an unknown 
mechanism. Previously, researchers have associated increased AMPK activity with decreased 
MPS during RE while also showing that both MPS and AMPK activity were significantly 
elevated 1 hour post-RE (Dreyer et al., 2006). Similar to Knudsen et al. these researchers 
suggested that signals promoting MPS, such as from mTOR and S6K1, may override the 
inhibitory effects of AMPK on MPS (Dreyer et al., 2006). Altogether, emerging evidence 
continues to suggest the inhibitory effect of AMPK on mTORC1 signaling and MPS can be 
abolished by mTORC1-activating signals. 
The data from Knudsen et al. highlight a disconnect between mTORC1 signaling and 
MPS. For example, MPS was impaired in AMPK-KD mice when compared with WT mice, 
despite similar mTORC1 signaling. Researchers have shown that mTORC1-dependent signaling 
is necessary for mechanical load-induced (i.e., RE) hypertrophy and S6K1 phosphorylation, but 
that mTORC1-dependent signaling is not necessary for mechanical load-induced increases in 
MPS (You et al., 2019). Specifically, the authors suggested that mTORC1-independent 
mechanisms may be responsible for the observed increases in MPS while mTORC1-dependent 
mechanisms are required for the post-translation modifications and autophagy necessary for 
hypertrophy (You et al., 2019). Moreover, the mTORC1-dependent and -independent 
mechanisms governing MPS have been shown to differ temporally following RE and may each 
be necessary for recovery from RE (West et al., 2016). While several potential mechanisms 
warrant discussion, explaining the malalignment in mTORC1 signaling and MPS reported by 
Knudsen et al. requires further investigation. 
The apparent effect of muscle glycogen on mTORC1 signaling and MPS is an intriguing 
observation; particularly, the additive effect of glycogen content on mTORC1 signaling and 
MPS in WT and AMPK-KD mice, respectively. Glycogen content is infrequently considered 
when studying RE and MPS but rather considered during prolonged, non-hypertrophic exercise. 
Investigating the role of glycogen content in mTORC1 signaling and MPS may reveal an 
overlooked connection between these cellular processes and improve our understanding of the 
mechanisms that govern skeletal muscle mass.  
When interpreting the results from Knudsen et al., an important limitation should be 
considered - in situ electrical stimulation, though a valuable technique, is not a direct RE-
mimetic and this may preclude the translation of the results to humans. Despite increasing 
mTORC1-S6K1 signaling, contractions at a stimulation frequency of 100 Hz likely recruits all 
motor units and would not mimic the normal recruitment pattern – the size principle – typically 
observed during voluntary RE in humans (Ljubicic et al., 2005). While the authors’ observations 
may indeed represent the true nature of these cellular processes, alternate models of RE should 
be utilized to confirm these results.  
Future research should endeavour to disentangle the interaction between mTORC1 
signaling and MPS. Specifically, investigating the role of skeletal muscle glycogen content on 
mTORC1 signaling and MPS, while addressing the limitations discussed herein, is intriguing and 
could yield novel results. Given the multitude of intricate responsibilities served by mTORC1 
and additional mechanisms underpinning MPS, incorporating the emerging “omic” techniques 
(e.g., metabolomics) could help pinpoint the central regulators of hypertrophy. Animal models 
certainly play a key role in scientific discovery, but researchers should work quickly to translate 
these findings to human models - since the ultimate objective is to improve skeletal muscle 
health in various human populations. Building upon results from Knudsen et al., researchers 
would do well to investigate the influence of glycogen manipulation on mTORC1 signaling and 
MPS within various human populations. Specifically, the effects of increased muscle glycogen 
content (i.e., “glycogen loading”) within an athletic population or the inability to breakdown 
glycogen in McArdle’s disease patients would each provide an interesting avenue for future 
research.  
As with any well-conducted study, upon completion, the findings generate more 
questions than answers. Knudsen et al. report an intriguing series of experiments that contribute 
nicely to the muscle physiology field and should be commended for their work. In addition to 
showing that AMPK is not necessarily an oppressive regulator of mTORC1, they highlight 
disparities between mTORC1 signaling and MPS while adding muscle glycogen to the multitude 
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